Federal Cannabis Reform 2026: Legislative Progress and Policy Changes

Executive Summary

Federal cannabis reform efforts intensified in May 2026 as lawmakers on Capitol Hill pushed multiple legislative initiatives aimed at ending federal prohibition and addressing banking, taxation, and criminal justice issues stemming from decades of criminalization. The renewed momentum comes amid a political landscape where 38 states have legalized medical cannabis and 24 have authorized adult-use programs, creating a stark disconnect between state-legal industries and federal Schedule I classification under the Controlled Substances Act. Key bills under consideration include comprehensive descheduling legislation, the SAFE Banking Act reintroduction, and amendments to Internal Revenue Code Section 280E that currently prevents cannabis businesses from deducting ordinary business expenses. The reform push represents the most significant federal cannabis policy activity since the Drug Enforcement Administration's 2024 notice of proposed rulemaking to reschedule cannabis to Schedule III, a process that remains pending before an administrative law judge as of May 2026.

The legislative efforts face a divided Congress where cannabis reform has historically garnered bipartisan support in polling but encountered procedural obstacles and leadership resistance. Industry stakeholders estimate that federal reform could unlock $10-15 billion in annual tax revenue while providing regulatory clarity for multi-state operators currently navigating conflicting state and federal frameworks. Patient advocates emphasize that continued Schedule I status restricts medical research and creates barriers to physician recommendations in states with legal programs.

Why Federal Cannabis Reform Matters in 2026

Federal cannabis policy affects 150 million Americans living in states with legal programs, a $33 billion legal industry, thousands of businesses operating in legal-state markets, and millions of patients relying on medical cannabis access. The current federal-state conflict creates operational, financial, and legal risks that ripple through every aspect of the cannabis ecosystem.

For multi-state operators and licensed businesses, federal prohibition creates existential challenges. Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, resulting in effective tax rates exceeding 70% for profitable cannabis companies. This tax burden has forced numerous operators into bankruptcy despite strong revenue growth. Banking access remains severely limited, with fewer than 800 of the nation's 4,500 federally-insured financial institutions willing to service cannabis clients, forcing many businesses to operate predominantly in cash.

For patients and consumers, federal prohibition restricts medical research, prevents physicians at Veterans Affairs facilities from recommending cannabis, and creates uncertainty about product safety standards. The lack of FDA oversight means no standardized testing protocols exist across state programs, and patients cannot transport medicine across state lines even between two legal states. Federal employees and military personnel face termination for legal state use, and immigrants risk deportation for cannabis involvement even in compliance with state law.

For state governments and regulators, the federal-state conflict complicates enforcement, creates banking deserts that increase public safety risks, and prevents interstate commerce that could reduce prices and improve market efficiency. States have collectively invested billions in regulatory infrastructure while operating in legal limbo, unable to coordinate across borders or access federal grants for public health initiatives related to cannabis.

The criminal justice implications remain profound. Despite state-level legalization, federal law enforcement conducted 186,000 cannabis-related arrests in 2025, predominantly for simple possession. Federal courts sentenced approximately 1,400 individuals to prison for cannabis offenses in 2025, with average sentences exceeding 30 months. The collateral consequences of federal cannabis convictions include lifetime bans on federal benefits, public housing, student loans, and immigration consequences.

Historical Timeline: The Path to Federal Reform

Federal cannabis prohibition spans nearly a century, from the Marihuana Tax Act of 1937 through the Controlled Substances Act of 1970 to the present reform movement that began gaining momentum in the 2010s.

Early Prohibition Era (1937-1970)

Congress passed the Marihuana Tax Act of 1937, effectively criminalizing cannabis through prohibitive taxation and registration requirements. The law followed a campaign led by Federal Bureau of Narcotics Commissioner Harry Anslinger that characterized cannabis as a dangerous drug associated with violence and moral decay. The Supreme Court struck down the Tax Act in Leary v. United States (1969) on Fifth Amendment grounds, finding that compliance with the registration requirement would violate the privilege against self-incrimination.

Controlled Substances Act and Schedule I Classification (1970-1996)

President Richard Nixon signed the Controlled Substances Act into law on October 27, 1970, as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The CSA established five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis was placed in Schedule I, defined as substances with high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. The classification was intended as temporary pending a commission review.

The National Commission on Marihuana and Drug Abuse, appointed by Nixon, recommended decriminalization in its 1972 report "Marihuana: A Signal of Misunderstanding." Nixon rejected the recommendation. The Drug Enforcement Administration, created in 1973, assumed enforcement authority. In 1988, DEA Administrative Law Judge Francis Young ruled that cannabis should be rescheduled, finding it "one of the safest therapeutically active substances known to man," but DEA Administrator John Lawn rejected the recommendation.

State Medical Cannabis Era Begins (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, becoming the first state to legalize medical cannabis. The law created immediate conflict with federal enforcement. The Department of Justice under President Bill Clinton threatened to revoke DEA registrations of physicians who recommended cannabis. In Conant v. Walters (2002), the Ninth Circuit ruled that physician recommendations were protected speech under the First Amendment.

The Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) that medical necessity was not a defense to federal prosecution, and in Gonzales v. Raich (2005) that Congress could criminalize intrastate cultivation and possession under the Commerce Clause even in states with medical programs. By 2012, 18 states and the District of Columbia had enacted medical cannabis laws despite federal prohibition.

Adult-Use Legalization and Federal Forbearance (2012-2017)

Colorado and Washington voters approved adult-use legalization on November 6, 2012. Deputy Attorney General James Cole issued guidance on August 29, 2013, directing federal prosecutors to deprioritize enforcement in states with robust regulatory systems, focusing resources on preventing distribution to minors, diversion to prohibition states, and involvement of criminal enterprises. The Cole Memorandum created a framework for state-federal coexistence without changing federal law.

Congress enacted the Rohrabacher-Farr Amendment in December 2014, prohibiting the Department of Justice from using appropriated funds to prevent states from implementing medical cannabis laws. The provision has been renewed in subsequent appropriations bills. The FinCEN guidance issued February 14, 2014, provided a pathway for financial institutions to service cannabis businesses while filing suspicious activity reports, though most banks declined to participate.

Sessions Rescission and Congressional Response (2017-2020)

Attorney General Jeff Sessions rescinded the Cole Memorandum on January 4, 2018, returning enforcement discretion to U.S. Attorneys. The move sparked bipartisan congressional backlash. The House of Representatives passed the SAFE Banking Act on September 25, 2019, by a vote of 321-103, marking the first time either chamber approved standalone cannabis reform legislation. The Senate declined to take up the measure.

The 2018 Farm Bill, signed December 20, 2018, removed hemp (cannabis with less than 0.3% delta-9 THC) from Schedule I, creating a legal hemp industry and highlighting the arbitrary nature of cannabis scheduling based on THC content. The Agriculture Improvement Act of 2018 transferred regulatory authority over hemp to the Department of Agriculture.

Democratic Control and Comprehensive Reform Bills (2021-2023)

The House passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act on December 4, 2020, and again on April 1, 2022, marking the first time a chamber of Congress voted to end federal cannabis prohibition. The legislation would deschedule cannabis, expunge federal convictions, and impose a 5% federal tax with revenue directed to communities impacted by the War on Drugs. The Senate did not advance the bill.

Senate Majority Leader Chuck Schumer introduced the Cannabis Administration and Opportunity Act on July 21, 2021, a comprehensive descheduling bill that would transfer regulatory authority to the FDA, ATF, and TTB while establishing a federal excise tax and social equity provisions. The bill did not receive a floor vote. President Joe Biden issued pardons for federal simple possession convictions on October 6, 2022, affecting approximately 6,500 individuals, and directed HHS and DOJ to review cannabis scheduling.

Rescheduling Process and Current Status (2023-2026)

The Department of Health and Human Services completed its scheduling review and recommended to the DEA on August 30, 2023, that cannabis be rescheduled from Schedule I to Schedule III. The recommendation, based on an FDA analysis, found that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a notice of proposed rulemaking on May 21, 2024, initiating the formal rescheduling process under the Administrative Procedure Act.

The DEA received more than 43,000 public comments during the comment period that closed July 22, 2024. Administrative law judge hearings began in December 2024 to evaluate the scientific and legal basis for rescheduling. As of May 2026, the process remains pending, with a final rule not expected until late 2026 at the earliest. Rescheduling to Schedule III would maintain federal prohibition but eliminate 280E tax penalties and facilitate medical research, while falling short of the full descheduling that reform advocates seek.

Key Players in the 2026 Reform Push

Federal cannabis reform involves a complex coalition of congressional champions, executive branch agencies, industry groups, advocacy organizations, and opposition forces, each with distinct interests and influence.

Congressional Leadership

Senate Majority Leader Chuck Schumer has positioned cannabis reform as a priority, having introduced comprehensive descheduling legislation and advocated for the SAFE Banking Act's inclusion in must-pass legislation. House Democratic leadership has repeatedly passed reform bills, though Republican control of the House in the 119th Congress shifts dynamics. Representative Dave Joyce, Republican co-chair of the Congressional Cannabis Caucus, and Representative Earl Blumenauer, longtime reform champion, lead bipartisan efforts. Senator Cory Booker has insisted that reform include social equity provisions and expungement, while Senator Ron Wyden chairs the Finance Committee with jurisdiction over tax reform.

Executive Branch Agencies

The Drug Enforcement Administration holds statutory authority over scheduling under 21 U.S.C. § 811 and has initiated the rescheduling process while maintaining enforcement discretion. The Department of Justice sets prosecution priorities and has historically oscillated between forbearance and aggressive enforcement depending on administration. The Department of Health and Human Services and the Food and Drug Administration conduct scientific evaluations of scheduling and would assume regulatory authority over cannabis as a drug if rescheduled or descheduled. The Treasury Department and Financial Crimes Enforcement Network regulate banking access and suspicious activity reporting requirements.

Industry Organizations

The Cannabis Trade Federation represents multi-state operators and advocates for federal reform that provides banking access and tax relief while maintaining state-regulatory frameworks. The National Cannabis Industry Association focuses on small business interests and social equity. The U.S. Cannabis Council represents large MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs, companies with combined annual revenue exceeding $8 billion that face effective tax rates above 70% under 280E. These operators have invested heavily in lobbying, spending a combined $4.2 million in 2025 according to federal disclosure reports.

Advocacy and Reform Groups

The National Organization for the Reform of Marijuana Laws has advocated for legalization since 1970 and maintains grassroots networks in all 50 states. The Drug Policy Alliance focuses on criminal justice reform and harm reduction, emphasizing expungement and community reinvestment. The Marijuana Policy Project has drafted model legislation adopted in multiple states. Americans for Safe Access represents medical cannabis patients and caregivers, emphasizing research access and physician freedom. The Last Prisoner Project focuses exclusively on cannabis prisoner release and record clearing.

Opposition Forces

Smart Approaches to Marijuana, founded by former Representative Patrick Kennedy, opposes legalization while supporting decriminalization and medical research. The organization argues that commercialization has led to increased youth use and impaired driving, citing data from Colorado and Washington. Law enforcement groups including the National Sheriffs' Association have historically opposed legalization, though some state and local law enforcement leaders now support reform. The Community Anti-Drug Coalitions of America receives federal funding and opposes legalization. Some addiction treatment providers and physicians' groups express concerns about normalization and lack of FDA approval.

Current Legislative Framework and Proposals

Multiple bills introduced in the 119th Congress address different aspects of federal cannabis policy, from comprehensive descheduling to incremental banking and tax reforms.

Controlled Substances Act and Current Scheduling

Cannabis remains classified under Schedule I of the Controlled Substances Act, 21 U.S.C. § 812, alongside heroin, LSD, and MDMA. Schedule I classification requires findings that a substance has high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. Federal penalties under 21 U.S.C. § 841 include up to five years imprisonment for possession with intent to distribute any amount, and mandatory minimum sentences of five years for 100 kilograms or 100 plants, and ten years for 1,000 kilograms or 1,000 plants.

Comprehensive Descheduling Legislation

The Cannabis Administration and Opportunity Act, reintroduced in February 2026, would remove cannabis from the Controlled Substances Act entirely within 180 days of enactment. The bill would transfer regulatory authority over cannabis commerce to the Alcohol and Tobacco Tax and Trade Bureau, establish a federal excise tax beginning at 10% and rising to 25% over five years, and create an Opportunity Trust Fund to support communities disproportionately impacted by prohibition. The legislation includes automatic expungement of federal cannabis convictions and resentencing for individuals currently incarcerated. The bill would prohibit federal interference with state cannabis laws while establishing minimum age requirements and restrictions on marketing to minors.

SAFE Banking Act

The Secure and Fair Enforcement Banking Act, passed by the House in 2019, 2020, and 2021 but never advanced by the Senate, was reintroduced in January 2026. The legislation would create a safe harbor for financial institutions providing services to state-legal cannabis businesses, prohibiting federal banking regulators from penalizing institutions solely for serving cannabis clients. The bill would protect ancillary businesses including landlords, vendors, and attorneys from money laundering liability under 18 U.S.C. § 1956 and 1957. Federal Reserve banks would be required to provide master accounts to institutions serving cannabis businesses. The legislation does not address tax reform or criminal justice issues.

280E Tax Reform

The Small Business Tax Equity Act would amend Internal Revenue Code Section 280E to exclude state-legal cannabis businesses from the provision that prohibits deduction of business expenses for trafficking in Schedule I or II substances. Current 280E application means cannabis businesses can deduct only cost of goods sold, disallowing deductions for rent, salaries, marketing, and other ordinary expenses available to all other businesses. The effective tax rate for profitable cannabis companies ranges from 55% to 75%, compared to 21% corporate rate for other industries. Standalone 280E reform has gained bipartisan support as a narrow fix that could pass even without comprehensive legalization.

State-by-State Legal Status

As of May 2026, 38 states, four territories, and the District of Columbia have legalized medical cannabis, while 24 states and two territories have authorized adult-use programs, creating a patchwork of regulations that federal reform would rationalize.

Adult-Use Legal States

California, the largest cannabis market with $5.3 billion in annual sales, permits adults 21 and older to possess up to one ounce and cultivate six plants. Proposition 64, approved in 2016, established a dual-licensing system with state and local approval required. Colorado, the first state to implement adult-use sales in January 2014, allows possession of one ounce and six plants with a 15% excise tax plus state and local sales taxes. Washington operates a state-licensed private market with no home cultivation, generating $559 million in excise tax revenue in 2025.

New York launched adult-use sales in December 2022 following legalization in March 2021, with possession limits of three ounces and home cultivation of six plants permitted. The state prioritized social equity applicants for initial licenses. Illinois generated $1.4 billion in adult-use sales in 2025, with 25% of licenses reserved for social equity applicants from communities with high arrest rates. Michigan's adult-use market reached $3.2 billion in 2025, the second-largest in the nation, with possession limits of 2.5 ounces and 12 plants.

Medical-Only States

Florida operates the largest medical-only program with 873,000 registered patients as of March 2026 and $2.1 billion in annual sales. The program, authorized by constitutional amendment in 2016, requires physician certification for qualifying conditions including cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn's disease, Parkinson's disease, and multiple sclerosis. Adult-use legalization appeared on the November 2024 ballot but failed to achieve the required 60% supermajority, receiving 57% approval.

Ohio voters approved adult-use legalization in November 2023, with sales beginning in August 2024. The state's medical program, launched in 2019, serves 128,000 patients. Pennsylvania's medical program, operational since 2018, has 425,000 active patients and generated $1.8 billion in sales in 2025. Adult-use legalization efforts have stalled in the Republican-controlled legislature despite polling showing 60% public support.

Prohibition States

Twelve states maintain complete prohibition of cannabis for any purpose: Idaho, Wyoming, Kansas, Nebraska, South Dakota, Wisconsin, Indiana, Kentucky, Tennessee, South Carolina, North Carolina, and Georgia. These states account for 58 million residents, or 17% of the U.S. population. Several prohibition states have decriminalized possession of small amounts, reducing penalties to civil fines rather than criminal charges. Federal reform would not compel these states to legalize but would eliminate federal penalties and allow interstate commerce, potentially reducing prices and increasing access even in prohibition states through neighboring state markets.

Market and Business Implications of Federal Reform

Federal cannabis reform would fundamentally restructure a $33 billion industry, unlocking institutional capital, enabling interstate commerce, reducing tax burdens, and consolidating a fragmented state-by-state market into a national industry.

280E Tax Relief and Profitability

Elimination of Section 280E restrictions would immediately improve cannabis company profitability by 20-40 percentage points according to industry analysts. Curaleaf, the nation's largest MSO with $1.4 billion in 2025 revenue, paid an effective tax rate of 72% on $180 million in operating income, resulting in $130 million in federal tax compared to $38 million if taxed at the standard 21% corporate rate. The $92 million difference represents capital that could fund expansion, debt reduction, or shareholder returns. Across the industry, 280E relief would free an estimated $3-4 billion annually for reinvestment.

Banking Access and Capital Markets

SAFE Banking Act passage would enable cannabis companies to access traditional banking services, reducing cash-handling costs estimated at 10-15% of revenue for security, transportation, and accounting. Public companies could list on major exchanges including the New York Stock Exchange and Nasdaq, currently prohibited due to federal illegality. Canadian MSOs including Canopy Growth, Tilray, and Cronos Group could enter the U.S. market without risking federal prosecution. Institutional investors including pension funds, mutual funds, and insurance companies could invest in cannabis stocks, potentially unlocking $50-100 billion in capital.

Interstate Commerce and Market Efficiency

Federal legalization would enable interstate commerce, currently prohibited even between legal states due to federal trafficking laws. Interstate commerce would allow cultivation in optimal climates, reducing production costs by an estimated 40-60%. California wholesale flower prices of $800-1,200 per pound could supply East Coast markets where wholesale prices reach $2,500-3,500 per pound. National brands could achieve economies of scale in manufacturing, marketing, and distribution. Analysts project interstate commerce could reduce consumer prices by 30-50% while improving product consistency and safety through national supply chains.

Consolidation and Market Structure

Federal reform would accelerate industry consolidation as large MSOs acquire smaller operators and institutional capital funds expansion. The top five MSOs—Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano—control 18% of the national market. Analysts project the top ten operators could control 40-50% of the market within five years of federal legalization, similar to alcohol industry concentration. Craft and boutique operators would occupy premium segments, while mass-market products would be dominated by large-scale producers. Social equity licensees face risk of being squeezed out by well-capitalized competitors unless protective policies are implemented.

Ancillary Business Growth

Federal reform would benefit ancillary businesses including real estate, technology, professional services, and manufacturing. Cannabis-focused real estate investment trusts could access traditional financing and list on major exchanges. Technology companies providing seed-to-sale tracking, point-of-sale systems, and compliance software would see expanded markets. Testing laboratories, packaging manufacturers, and extraction equipment suppliers would benefit from interstate commerce and increased production scale. Employment in the cannabis industry, currently estimated at 440,000 full-time equivalent positions, could double within five years of federal legalization.

What Policy Experts and Stakeholders Say

Policy analysts, industry leaders, patient advocates, and law enforcement officials hold diverse perspectives on federal reform timing, structure, and implications.

According to the Brookings Institution's analysis published in March 2026, federal cannabis reform is inevitable given state-level momentum and public opinion, but the structure of reform will determine whether the industry develops as a public health-oriented regulatory model or a commercialized market dominated by large corporations. The report emphasized that descheduling without comprehensive regulation could replicate alcohol industry problems including aggressive marketing, product proliferation, and corporate consolidation.

The RAND Corporation's assessment released in January 2026 found that federal legalization would reduce cannabis prices by 40-60% through interstate commerce and economies of scale, with uncertain effects on youth use and impaired driving. The analysis noted that state-level legalization has not produced the dramatic increases in youth use that opponents predicted, but also has not achieved the criminal justice benefits that advocates promised, with arrest rates for Black individuals remaining disproportionately high even in legal states.

Industry leaders emphasize the urgent need for banking access and tax reform. According to testimony before the Senate Banking Committee in March 2026, the CEO of a multi-state operator described the operational burden of operating predominantly in cash, including $2 million annually in security costs, difficulty paying vendors and employees, and inability to access credit for expansion. The executive argued that continued federal prohibition creates public safety risks and competitive disadvantages compared to alcohol and tobacco industries.

Patient advocacy organizations stress that Schedule I classification restricts medical research and physician access. According to Americans for Safe Access, only 15 clinical trials of cannabis for medical conditions are currently underway in the United States compared to hundreds of trials for other Schedule III substances. Veterans' groups have advocated for allowing VA physicians to recommend medical cannabis in states with legal programs, currently prohibited by federal law. The American Cancer Society issued a statement in February 2026 supporting rescheduling to facilitate research while maintaining that more evidence is needed to establish efficacy for specific conditions.

Law enforcement perspectives have shifted significantly, with the Law Enforcement Action Partnership, representing current and former police, prosecutors, and judges, endorsing federal legalization and expungement. The organization's position paper released in April 2026 argued that cannabis prohibition has failed to reduce use while diverting resources from serious crimes and damaging police-community relations. However, the National Sheriffs' Association maintains opposition to legalization, citing concerns about impaired driving and lack of reliable roadside testing technology.

Social equity advocates warn that federal reform could worsen racial disparities if not carefully structured. According to the Minority Cannabis Business Association, Black entrepreneurs hold less than 2% of cannabis licenses nationally despite being arrested for cannabis offenses at four times the rate of white individuals. The organization has called for federal reform to include automatic expungement, reinvestment in affected communities, and set-asides for social equity applicants in federal licensing.

What Comes Next: Timeline and Scenarios

Federal cannabis reform in 2026 faces multiple pathways including standalone legislation, attachment to must-pass bills, administrative rescheduling, or continued gridlock, with outcomes dependent on congressional composition, presidential priorities, and public pressure.

Near-Term Legislative Calendar

The Senate Banking Committee scheduled a markup of the SAFE Banking Act for June 2026, with Chairman Sherrod Brown indicating bipartisan support for moving the bill to the floor. House leadership has not committed to floor time for cannabis legislation in the current session. The appropriations process beginning in July 2026 presents an opportunity to attach cannabis provisions to must-pass spending bills, a strategy that succeeded with hemp legalization in the 2018 Farm Bill. The National Defense Authorization Act, typically enacted in December, has been identified as a potential vehicle for SAFE Banking provisions.

Administrative Rescheduling Process

The DEA administrative law judge hearings on rescheduling cannabis to Schedule III are expected to conclude in summer 2026, with a recommended decision to the DEA Administrator anticipated in fall 2026. The Administrator would then issue a final rule, subject to a 30-day congressional review period under the Congressional Review Act. The earliest a final rescheduling rule could take effect is January 2027. Rescheduling would eliminate 280E tax penalties and facilitate medical research but would maintain federal prohibition on possession and distribution, leaving state-legal businesses in violation of the Controlled Substances Act.

Presidential Election Impact

The November 2026 midterm elections will determine congressional control for the final two years of the current presidential term. Polling shows cannabis legalization supported by 70% of Americans including majorities of both parties, creating political incentives for candidates to embrace reform. However, cannabis has historically been a low-salience issue that does not drive voter behavior, limiting its impact on electoral outcomes. Presidential candidates for the 2028 election are expected to stake out positions on federal reform during the primary season beginning in late 2026.

Potential Scenarios

The incremental reform scenario involves passage of SAFE Banking and 280E relief without comprehensive descheduling, providing industry relief while maintaining prohibition. This outcome is considered most likely by congressional observers given bipartisan support for narrow banking and tax fixes. The comprehensive reform scenario would involve passage of full descheduling legislation with expungement and social equity provisions, fundamentally ending federal prohibition. This outcome requires unified Democratic control or significant Republican defections, considered unlikely in the current Congress. The status quo scenario involves continued gridlock with no major legislative action, leaving the industry dependent on administrative rescheduling and state-level progress. The regulatory reform scenario involves rescheduling to Schedule III through the administrative process, providing partial relief without congressional action.

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.deadiversion.usdoj.gov/21cfr/21usc/index.html
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 21, 2024) — https://www.federalregister.gov/
• Department of Health and Human Services Cannabis Scheduling Recommendation (August 30, 2023) — https://www.hhs.gov/
• Congressional Research Service, "Marijuana: Medical and Retail—Selected Legal Issues" (Updated 2026) — https://crsreports.congress.gov/
• National Conference of State Legislatures, State Medical Cannabis Laws — https://www.ncsl.org/health/state-medical-cannabis-laws
• Cannabis Administration and Opportunity Act, S. 1698, 119th Congress — https://www.congress.gov/
• SAFE Banking Act, H.R. 2891, 119th Congress — https://www.congress.gov/
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• Cole Memorandum on marijuana enforcement priorities (August 29, 2013) — https://www.justice.gov/
• RAND Corporation, "Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions" — https://www.rand.org/
• Brookings Institution, "The Cannabis Policy Landscape" — https://www.brookings.edu/
• Marijuana Policy Project, State-by-State Laws — https://www.mpp.org/states/
• NORML, Federal Marijuana Laws and Penalties — https://norml.org/laws/federal-penalties-2/
• U.S. Cannabis Council Industry Reports — https://www.uscannabishouncil.com/